## (19) World Intellectual Property Organization

International Bureau





(43) International Publication Date 9 December 2004 (09.12.2004)

PCT

## (10) International Publication Number WO 2004/105788 A1

A61K 38/24, (51) International Patent Classification7: A61P 15/08

(21) International Application Number:

PCT/IB2004/001813

2 June 2004 (02.06.2004) (22) International Filing Date:

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data: 10/452,926

3 June 2003 (03.06.2003)

(71) Applicant (for all designated States except US): FER-RING B.V. [NL/NL]; P.O. Box 3129, 2130 Polaris Avenue 144, NL-2132 JX Hoofddorp (NL).

(72) Inventor; and

(75) Inventor/Applicant (for US only): FILICORI, Marco [IT/IT]; Vicolo Malgrado 2/8, I-40125 Bologna (IT).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

## Published:

- with international search report
- with amended claims

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: UNITARY COMBINATION OF FSH AND hCG



(57) Abstract: A novel ovulatory induction paradigm entails administration of hCG in combination with FSH during all stages of treatment, where the ratio of FSH to hCG is adjusted to optimize ovulatory stimulation and minimize complications. The use of compositions characterized by various FSH:hCG ratios enables the practitioner readily to tailor the treatment regimen and accommodate different therapeutic goals as well as individual patient responses to gonadotropin administration.